People | May 03, 2026
Sanofi India appoints Rahul Bhatnagar as Chairman of Board of Directors
Rahul Bhatnagar succeeds Aditya Narayan, who completed a decade-long distinguished tenure
Rahul Bhatnagar succeeds Aditya Narayan, who completed a decade-long distinguished tenure
While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules
The George Institute India’s large-scale community-based model demonstrates reduced depression, self-harm, and suicide risk among adolescents in Delhi and Vijayawada
Reshaped by COVID-19, rising test demand, and a shift toward decentralized diagnostics, qPCR has evolved from niche academic use to a core clinical engine
With the convergence of AI, robotics, and neuroscience, Motorica is advancing toward more intuitive, intent-driven prosthetic systems
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
Landmark agreement opens market access, mobility pathways, and institutional collaboration for Ayurveda, Yoga, and holistic healthcare services
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
Experts call for integrated, evidence-based approaches to tackle rising dengue, malaria, and chikungunya burden in Indian cities
Subscribe To Our Newsletter & Stay Updated
